Mirum Pharmaceuticals, Inc. MIRM Debt-to-equity

Debt-to-equity at other companies

Gilead SciencesGILD

2.2×+1.0×

Rhythm Pharmaceuticals, Inc.RYTM

0.9×-5.1×

LQD

Liquidia CorporationLQDA

0.1×-0.1×

ALN

Alnylam PharmaceuticalsALNY

0.2×-0.9×

Arrowhead ResearchARWR

0.2×0.0×

Zevra Therapeutics, Inc.ZVRA

0×-0.5×

FAQ

What is Mirum Pharmaceuticals, Inc.'s debt-to-equity?

Mirum Pharmaceuticals, Inc. (MIRM) reported debt-to-equity of 0.1× in Q1 2026.

How has Mirum Pharmaceuticals, Inc.'s debt-to-equity changed year-over-year?

Mirum Pharmaceuticals, Inc.'s debt-to-equity increased by 50.4% year-over-year, from 0× to 0.1×.

What is the long-term trend for Mirum Pharmaceuticals, Inc.'s debt-to-equity?

Over 5 years (2020 to 2025), Mirum Pharmaceuticals, Inc.'s debt-to-equity has grown at a 10.1% compound annual growth rate (CAGR), from 0× to 0×.

What does debt-to-equity mean?

Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.